Niederer Kraft Frey has advised CoinShares, Europe’s largest digital asset investment firm with over USD 1.6 billion in AUM, in connection with its first-time issuer application and the listing of its physically-backed FTX Token exchange
Stadtcasino Baden has acquisted a majority stake in Casinò Locarno. With this acquisition, the group extends its footprint to the Italian speaking part of Switzerland. Stadtcasino Baden and its subsidiaries are one of the largest
DKSH Holding has acquired Terra Firma, a leading distributor of specialty chemicals in North America. With this acquisition, DKSH expands its performance materials business unit platform to the US and Canada. The transaction is an
Niederer Kraft Frey advised the Beijing company Lepu Medical Technology on its successful USD 224 million offering and listing of global depositary receipts on SIX Swiss Exchange within the framework of the China-Switzerland Stock Connect
Schellenberg Wittmer has advised Asker Healthcare Group on its acquisition of all shares in the Swiss medical supplies distributor Aichele Medico from the founding family and the company’s management team. Asker Helathcare, headquartered in
Walder Wyss has successfully represented a Swiss high-tech company both in arbitration proceedings (seated in Geneva and adjudicated under the WIPO Arbitration Rules) and before the Swiss Federal Supreme Court. The law firm has defended
As we informed last 5th September here, Zur Rose Group has successfully placed newly issued shares raising gross proceeds of approximately CHF 44 million and CHF 95 million guar
CMS Switzerland has represented Diffulivre, a Swiss company and member of the Hachette Group, in an appeal before the Swiss Supreme Court brought against the judgment by the Swiss Administrative Court of 30 October 2019 concerning the
Homburger‘s partner Felix Dasser has been re-elected President of the Swiss Arbitration Association (ASA) for another term by the members of the association. Felix Dasser has been a partner of Homburger since 2000 and was
Versantis, a private Swiss-based clinical stage biotechnology company focused on addressing the growing unmet medical needs in liver diseases, is to be sold to Genfit. With this acquisition, Genfit intends to expand its product portfolio
